评估共同决策干预对肾细胞癌患者的影响：SDM-RCC研究方案
Evaluating the Impact of a Shared Decision-making Intervention for Patients with Renal Cell Carcinoma: The SDM-RCC Study Protocol
影响因子:9.30000
分区:医学1区 Top / 泌尿学与肾脏学1区 肿瘤学2区
发表日期:2025 Apr
作者:
Cato C Bresser, Mirjam M Garvelink, Birgitta M M van den Berg, Franklin C K Dolk, Paul B van der Nat, Harm H E van Melick
摘要
SDM-RCC研究的目的是评估全面共享决策（SDM）干预对肾细胞癌患者（RCC）对决策过程和结果的影响。干预措施包括在线患者决策辅助工具（PTDA）和卫生保健专业人员（HCP）的培训，用于使用PTDA和SDM。这项研究是六家荷兰医院的多中心，前瞻性预测试队列，重点是局部或转移性RCC的患者。主要结果是使用选项5分数测量的决策过程的观察到的质量。次要结果包括决策过程的质量，决策质量以及干预措施的实施（用户统计和访谈）。定量分析将在问卷数据上进行，而定性分析将使用基于既定框架的编码进行访谈。研究结果可以提高对患者，HCP和观察者观点的RCC患者的决策过程的了解。实施的SDM工具有望支持决策过程。患者摘要：我们正在对工具的效果进行试验，以支持面临治疗决策的肾脏癌患者共同决策。本文概述了将用于试用的协议。
Abstract
The aim of the SDM-RCC study is to evaluate the impact of a comprehensive shared decision-making (SDM) intervention for patients with renal cell carcinoma (RCC) on the decision-making process and outcomes. The intervention includes online patient decision aids (PtDAs) and training of health care professionals (HCPs) in the use of PtDAs and SDM. The study is a multicenter, prospective pretest-posttest cohort in six Dutch hospitals, focusing on patients with localized or metastatic RCC. The primary outcome is the observed quality of the decision-making process, measured using OPTION-5 scores. Secondary outcomes include perceived quality of the decision-making process, decision quality, and implementation of the intervention (user statistics and interviews). Quantitative analysis will be performed on questionnaire data, while qualitative analysis will be performed on interviews using coding based on established frameworks. The study results could improve understanding of the decision-making process for RCC patients from patient, HCP, and observer perspectives. The SDM tool implemented is expected to support the decision-making process. PATIENT SUMMARY: We are conducting a trial on the effects of a tool to support shared decision-making by patients with kidney cancer who are facing treatment decisions. This paper outlines the protocol that will be used for the trial.